Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.70 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181654 | 0.90 | HDAC3 (0.81) | KCNH2HDAC3HDAC2HDAC1NCOR2 | |
| SCHEMBL19230849 | 0.87 | KCNH2 (1.00) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL19230846 | 0.86 | KCNH2 (0.85) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL19230850 | 0.84 | KCNH2 (0.85) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL20181502 | 0.84 | HDAC3 (1.00) | KCNH2HDAC3HDAC2HDAC1NCOR2 | |
| SCHEMBL19231010 | 0.84 | HDAC3 (0.71) | KCNH2HDAC3HDAC2HDAC1NCOR2 | |
| SCHEMBL23960888 | 0.83 | HDAC3 (0.73) | KCNH2HDAC3HDAC2HDAC1NCOR2 | |
| SCHEMBL19230847 | 0.83 | KCNH2 (0.82) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL15922983 | 0.83 | HDAC3 (1.00) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL4578698 | 0.82 | KCNH2 (0.75) | KCNH2HDAC3HDAC2HDAC1NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20170240535-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | REGENACY PHARMACEUTICALS, LLC | 2017-08-24 | — | — | US | disclosed |
| WO-2017136451-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | REGENACY PHARMACEUTICALS, LLC (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | KCNH2 890/4885HDAC3 1962/4885HDAC2 2719/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KCNH2 4805/4885HDAC3 3028/4885HDAC2 2920/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KCNH2 4805/4885HDAC3 3028/4885HDAC2 2920/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KCNH2 2721/4885HDAC3 2178/4885HDAC2 1342/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | KCNH2 4855/4885HDAC3 1324/4885HDAC2 1552/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | KCNH2 4521/4885HDAC3 1673/4885HDAC2 1526/4885 |
| US-20170240535-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | HDAC1, HDAC2, HDAC11 | KCNH2 4701/4885HDAC3 6/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.